Coronavirus Highlights: India Reports 9,283 New Covid Cases In Last 24 Hours

The number of positive cases detected during the day was seven more from the previous day with the positivity rate increasing to 0.66 per cent from 0.56 per cent on Tuesday.

The COVID-19 death count remained unchanged at 13,593, he said.

Recoveries marginally outnumbered new cases with 782 people getting discharged in the last 24 hours, aggregating to 26,77,607, leaving 8,484 active infections, a health department bulletin said.

Of the fresh cases, two were registered in East Sikkim and one in West Sikkim.

With 32 patients getting discharged from hospitals in the last 24 hours, the tally of recovered cases rose to 8,16,888, it said.

The day also saw 546 discharges, taking the total number of recoveries in the state so far to 29,49,629, a health department bulletin said.

Two new fatalities were reported from Kangra, while one from Una district.

Of the fresh cases, 25 were from Jammu division and 149 from Kashmir division, the officials said.

Of the fresh cases, seven were detected in Dimapur, two in Mokokching and one in Kohima district, he said.

With this, the tally of infections in the district has risen to 4,12,107, which includes 8,710 fatalities, he said.

The number of deaths reported was 308 which raised the count to 38,353, said an official press release.

In a letter to Nagaland, Sikkim, Maharashtra, Kerala, Goa, Manipur, Meghalaya, Mizoram, Jammu and Kashmir, Punjab, Rajasthan, West Bengal and Ladakh, Union Health Secretary Rajesh Bhushan stressed on maintaining high testing rates given the recent increase in travelling due to events like marriages, festivals and vacations that have recently concluded or are underway.

"A decrease in testing would undermine the actual infection spread within the community," Mr Bhushan said in the letter.

As part of the deal, Cadila will transfer the DNA vaccine technology to Enzychem, which will make and sell the vaccine, ZyCoV-D, within its territory under the Cadila trademark. Cadila will get license fees and royalty payments, the company said in a filing to stock exchanges.

As India was slammed by its second major Covid wave earlier this year, researchers at the All India Institute of Medical Sciences in Delhi analyzed data from 2,714 of the hospital's health workers who were showing signs of infection and underwent RT-PCR testing between April 15 and May 15, according to a study published in The Lancet Infectious Diseases journal. At the start of the country's vaccination campaign in January, staff at AIIMS had exclusively been offered Covaxin, a shot co-developed by India's state-funded health research agency and local company Bharat Biotech International Ltd.